



**HAL**  
open science

## New insights into the genetic basis of premature ovarian insufficiency: Novel causative variants and candidate genes revealed by genomic sequencing

Sylvie Jaillard, K.W. Bell, Linda Akloul, K Walton, Kenneth Mcelreavy, W.A. Stocker, M. Beaumont, C Harrisson, Tiina Jääskeläinen, J.J. Palvimo, et al.

### ► To cite this version:

Sylvie Jaillard, K.W. Bell, Linda Akloul, K Walton, Kenneth Mcelreavy, et al.. New insights into the genetic basis of premature ovarian insufficiency: Novel causative variants and candidate genes revealed by genomic sequencing. *Maturitas*, 2020, 141, pp.9-19. 10.1016/j.maturitas.2020.06.004 . hal-02931925

**HAL Id: hal-02931925**

**<https://hal.science/hal-02931925v1>**

Submitted on 10 Sep 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**New insights into the genetic basis of premature ovarian insufficiency: novel causative variants and candidate genes revealed by genomic sequencing**

**Running title: New insights into the genetic basis of POI**

Sylvie Jaillard<sup>1,2,3</sup>, Katrina Bell<sup>3</sup>, Linda Akloul<sup>4</sup>, Kelly Walton<sup>5</sup>, Kenneth McElreavy<sup>6</sup>, William A. Stocker<sup>5,7</sup>, Marion Beaumont<sup>2</sup>, Craig Harrisson<sup>5</sup>, Tiina Jääskeläinen<sup>8</sup>, Jorma J. Palvimo<sup>8</sup>, Gorjana Robevska<sup>3</sup>, Erika Launay<sup>2</sup>, Anne-Pascale Satié<sup>1</sup>, Nurin Listyasari<sup>9</sup>, Claude Bendavid<sup>10,11</sup>, Rajini Sreenivasan<sup>3</sup>, Solène Duros<sup>12</sup>, Jocelyn van den Bergen<sup>3</sup>, Catherine Henry<sup>2</sup>, Mathilde Domin-Bernhard<sup>12</sup>, Laurence Cornevin<sup>2</sup>, Nathalie Dejuçq-Rainsford<sup>1</sup>, Marc-Antoine Belaud-Rotureau<sup>1,2,13</sup>, Sylvie Odent<sup>4,14</sup>, Katie L Ayers<sup>3,15</sup>, Célia Ravel<sup>1,13</sup>, Elena J Tucker<sup>3,15\*</sup>, Andrew H Sinclair<sup>3,15\*</sup>

- 1- Univ Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé, environnement et travail) - UMR\_S 1085, F-35000 Rennes, France
- 2- CHU Rennes, Service de Cytogénétique et Biologie Cellulaire, F-35033 Rennes, France
- 3- Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, VIC Australia, 3052
- 4- CHU Rennes, Service de Génétique Clinique, CLAD Ouest, F-35033 Rennes, France
- 5- Department of Physiology, Monash Biomedicine Discovery Institute, Monash University, VIC Australia, 3800
- 6- Institut Pasteur, CNRS – UMR\_3738, Paris, France
- 7- Department of Chemistry and Biotechnology, Swinburne University of Technology, Hawthorn, VIC Australia, 3122
- 8- Institute of Biomedicine, University of Eastern Finland, Kuopio, FI-70211 Kuopio, Finland
- 9- Doctoral Program of Medical and Health Sciences, Faculty of Medicine Diponegoro University, Semarang, Indonesia
- 10- INRAE, INSERM, Univ Rennes, Institut NuMeCan, Rennes, Saint-Gilles, France
- 11- Laboratoire de Biochimie et Toxicologie; CHU Rennes, Univ Rennes, Rennes, France
- 12- CHU Rennes, Département de Gynécologie Obstétrique et Reproduction Humaine, F-35033 Rennes, France
- 13- CHU Rennes, Service de Biologie de la Reproduction-CECOS, F-35033 Rennes, France

14- Univ Rennes, CNRS UMR 6290 Institut de Génétique et Développement, F-35000 Rennes, France

15- Department of Paediatrics, University of Melbourne, Melbourne, VIC Australia, 3052

\*Co-senior authors of this study

**Corresponding authors:** Sylvie Jaillard, [sylvie.jaillard@chu-rennes.fr](mailto:sylvie.jaillard@chu-rennes.fr); Elena J Tucker, [elena.tucker@mcri.edu.au](mailto:elena.tucker@mcri.edu.au)

### Highlights

- Our study has provided new insights or strengthened recent claims about the etiology of premature ovarian insufficiency.
- Genomic sequencing of patients with premature ovarian insufficiency or diminished ovarian reserve reveals novel causative variants in *STAG3*, *GDF9*, *FANCM*, and *FSHR*, and new candidate genes, *NRIP1*, *XPO1*, and *MACF1*.
- We validate that *GDF9* and *FANCM* are responsible for autosomal recessive premature ovarian insufficiency.
- The inability to diagnose some patients is probably the result of the genetic heterogeneity of premature ovarian insufficiency, incomplete understanding of its genetics, and sequencing of singleton DNA.

### Abstract

Ovarian deficiency, including premature ovarian insufficiency (POI) and diminished ovarian reserve (DOR), represents one of the main causes of female infertility. POI is a genetically heterogeneous condition but current understanding of its genetic basis is far from complete, with the cause remaining unknown in the majority of patients. The genes that regulate DOR have been reported but the genetic basis of DOR has not been explored in depth. Both conditions are likely to lie along a continuum of degrees of decrease in ovarian reserve. We performed genomic analysis via whole exome sequencing

(WES) followed by *in silico* analyses and functional experiments to investigate the genetic cause of ovarian deficiency in ten affected women. We achieved diagnoses for three of them, including the identification of novel variants in *STAG3*, *GDF9*, and *FANCM*. We identified potentially causative *FSHR* variants in another patient. This is the second report of biallelic *GDF9* and *FANCM* variants, and, combined with functional support, validates these genes as *bone fide* autosomal recessive “POI genes”. We also identified new candidate genes, *NRIP1*, *XPO1*, and *MACF1*. These genes have been linked to ovarian function in mouse, pig, and zebrafish respectively, but never in humans. In the case of *NRIP1*, we provide functional support for the deleterious nature of the variant via SUMOylation and luciferase/ $\beta$ -galactosidase reporter assays. Our study provides multiple insights into the genetic basis of POI/DOR. We have further elucidated the involvement of *GDF9*, *FANCM*, *STAG3* and *FSHR* in POI pathogenesis, and propose new candidate genes, *NRIP1*, *XPO1*, and *MACF1*, which should be the focus of future studies.

## Keywords

Premature ovarian insufficiency, Female infertility, Genomics

## 1. Introduction

Women are born with their future oocyte supply, which is established during development and reaches its maximum size of ~5 million germ cells around 20 weeks of gestation. After this peak, there is a steady atresia of oocytes with ~1-2 million by birth, further depleted to about half a million by menarche [1,2]. After menarche, women lose an average of 1000 oocytes per month, one of which completes maturation and is ovulated as part of the menstrual cycle [3]. The number of oocytes within each woman, corresponding to the ovarian reserve, is variable [4]. The cyclic oocyte maturation and loss of ovarian reserve occurs until menopause at an average age of 51 in the western world.

Ovarian deficiency, including premature ovarian insufficiency (POI) and diminished ovarian reserve (DOR), is one of the main causes of female infertility. A DOR is mostly the consequence of age but is considered abnormal if it occurs before the age of 40 (10% of women) [4]. In contrast, premature ovarian insufficiency (POI) is characterized by perturbation or cessation of the menstrual cycle along with elevated gonadotropins before the age of 40, affecting as many as 1 in 100 women. There is no evidence that DOR is a precursor of POI and women under 40 can have a DOR without POI. Nevertheless, these conditions are likely manifestations along a continuum of ovarian deficiency with different severity of decrease in ovarian reserve. POI can be devastating for affected women who face

infertility, as well as an increased risk of co-morbidities such as cardiovascular disease, mental health problems, osteoporosis and earlier mortality [5,6]. The cause of POI is manifold. It can be secondary to medical interventions or can occur as part of autoimmune conditions, metabolic conditions or genetic syndromes. There is a tendency for affected individuals to have affected family members, indicating the role of inheritance in the condition [7,8]. The genetic basis of POI is further demonstrated by the discovery of causative variants in over 50 different genes [6]. These genes have diverse roles including metabolism, folliculogenesis, gonadogenesis, oogenesis, DNA damage repair, apoptosis, hormone signaling, autoimmunity and more. Current understanding of the genetic basis of POI, however, is far from complete, with the cause remaining unknown in the majority of patients, particularly those with sporadic and isolated POI. Key regulating genes of DOR have also been reported [9] but the genetic basis of DOR has not been explored in depth. Importantly, overlapping genetic background has been reported for POI and DOR [10] providing rationale for testing both conditions using similar methods.

In this study, we have used whole-exome sequencing (WES) followed by thorough variant curation and functional validation to investigate the genetic cause of POI and DOR in a small cohort of 10 patients. All patients had isolated POI or DOR with no related medical history, and were initially analysed as singletons. We were able to provide likely genetic diagnoses to three patients who harboured novel variants in the known POI-related genes *STAG3*, *GDF9*, and *FANCM*. Another patient had variants of uncertain significance with high clinical relevance in *FSHR*. We also propose the potential involvement of variants in *NRIP1*, *XPO1*, and *MACF1*, three genes known to have a role in ovarian biology but never before associated with human POI.

## **2. Material and methods**

### **2.1. Ethical adherence and participants**

Written informed consent was obtained from all participants. All procedures were in accordance with the ethical standards of the Ethics Committee of Rennes University Hospital and the French law (favourable opinion from the CCTIRS - Comité Consultatif sur le Traitement de l'Information en matière de Recherche dans le domaine de la Santé - for the study).

Patients were recruited for the study after clinical consultation. They were all of Caucasian origin. All patients underwent cytogenetic analysis demonstrating normal 46,XX karyotype, and normal microarray (Agilent 180K), were negative for *FMR1* premutation and auto-antibodies (when available). Parental DNA was not available for WES but was retrospectively obtained for three patients.

### **2.2. Methods**

### 2.2.1. General molecular techniques

Genomic DNA was extracted from EDTA-blood samples with the NucleoSpin® Blood XL kit (Macherey-Nagel, Düren, Germany) and were assessed by NanoDrop™ 1000 spectrophotometer and Qubit dsDNA BR Assay (Thermo Fisher Scientific, Waltham, MA, USA).

Selected SNVs were validated by Sanger sequencing using BigDye v3.1 Terminators (Applied Biosystems, Foster City, CA, USA) and ABI 3130X. Primer sequences are available on request.

Phasing was performed by cloning in the pGEM-T Easy Vector (Promega Corporation, Madison, WI, USA) (detailed method in Supplementary File 1).

Blood RNA was extracted with a Nucleospin RNA blood kit (Macherey Nagel, Düren, Germany) according to the manufacturer's instructions. An additional DNase treatment was performed using the RQ1 RNase-Free DNase kit (Promega Corporation, Madison, WI, USA). Reverse transcription (RT) was performed on DNase-treated RNA using the GoScript™ Reverse Transcription System (Promega Corporation, Madison, WI, USA) as per manufacturer's protocols. To verify lack of residual genomic DNA in downstream reactions, control reactions were included without reverse transcriptase (-RT).

### 2.2.2. Whole-exome sequencing (WES)

DNA underwent WES at the Australian Genome Research Facility (AGRF). Exome capture was performed with Agilent SureSelect Human All Exon V6 (Agilent) and sequencing was performed on the NovaSeq 6000 (Illumina). All WES data were processed using Cpipe [11] and deposited into SeqR for analysis (<https://seqr.broadinstitute.org/>).

We performed two phases of analysis – the first focused on gene priority and the second focused on variant priority, as previously described [6]. MAF and tolerance of genes to missense and/or loss-of-function (LoF) variation were assessed in the public database gnomAD (<https://gnomad.broadinstitute.org/>). Variant pathogenicity was predicted *in silico* using Mutation Taster (<http://www.mutationtaster.org/>), Polyphen-2 (<http://genetics.bwh.harvard.edu/pph2/>), SIFT/Provean (<http://provean.icvi.org/>), DANN (Deleterious Annotation of genetic variants using Neural Networks) score [12] and CADD (Combined Annotation-Dependent Depletion) score (<https://cadd.gs.washington.edu/snv>). The conservation of affected nucleotides and residues in mammals, birds, reptiles and fish was also taken into account with GERP (Genomic Evolutionary Rate Profiling) score and Multiz Alignments of 100 vertebrates (UCSC Genome Browser <https://genome.ucsc.edu/>). Variants were curated using the American College of Medical Genetics and Genomics (ACMG) criteria, adapted for use by the Victorian Clinical Genetics Service [13]. The effects of

the missense mutations identified were assessed using the HOPE database [14] for the clinically relevant variants.

### **2.2.3. Analysis of sensitivity to chromosomal breakage**

72 h blood culture was performed with phytohemagglutinine, without treatment and after exposure to Mitomycin C ( $10^{-7}$  M, 30 ng/ml final concentration) (Sigma-Alrich, Saint-Louis, MI, USA) added after 24 h of culture. Metaphase spreads were colored by Giemsa. Baseline and DNA-induced chromosome breakage and rearrangements were scored on 50 metaphases in the patient and in a control. Two assays were performed on two different samples obtained four months apart.

### **2.2.4. Enzyme-linked immunosorbent assays (*GDF9* gene)**

ELISA sandwich assays were performed on serum of the patient using two GDF-9 ELISA kits (AnshLabs, Webster, TX, USA and LifeSpan BioSciences, Inc., Seattle, WA, USA) according to the manufacturers' protocols. For the AnshLabs kit, the antibodies were raised from full-length GDF9 protein, and detect the pro-region (aa 25-319) and mature region (aa 320-454). For the LifeSpan BioSciences kit, capture and detection antibodies are rabbit polyclonal antibodies affinity purified, standard and immunogen are a recombinant protein produced in E.coli encoding aa 320-454, and the epitopes recognized by the polyclonal antibodies have not been mapped. Fluorescence was measured using the Varioskan Flash (Thermo Fisher Scientific, Waltham, MA, USA) and iMark™ Microplate Absorbance Reader (Bio-Rad, Hercules, CA, USA).

### **2.2.5. Expression plasmids**

Wild-type human *GDF9* and *BMP15* expression plasmids containing N-terminal poly-histidine tags have been described previously [15]. Pro374Leu and Leu265\* variants were inserted into the WT His-tagged GDF9 plasmid via *in vitro* site-directed mutagenesis.

Expression plasmid with the *NRIP1* variant was created by site-directed mutagenesis of the previously described pSG5-HA-RIP140-WT expression vector [16] to generate pSG5-HA-RIP140-STOP1087MUT.

### **2.2.6. Western blot**

Transient transfection of HEK293 cells with GDF9 variants either alone or in combination with BMP15, followed by Western blotting of conditioned media and cell lysates was carried out as described previously [17]. To detect precursor and mature forms of GDF9 in conditioned media and cell lysates, blots were probed with mAb-53/1 (Oxford Brookes University, Oxford, UK, 1:5000), which is targeted to an epitope near the C-terminus of GDF9 [18]. Recombinant human GDF9 mature domain (R&D Systems, Minneapolis, MN, USA - 8266-G9-010) was used as reference. To detect BMP15 and GDF9 precursors in cell lysates, blots were probed with anti-6X-His (R&D Systems – MAB050, 1:2000).

COS1 cells were transfected with pSG5-HA-RIP140-WT or pSG5-HA-RIP140-STOP1087MUT alone or co-transfected with pSG5-His-SUMO-1 or pSG5-SUMO-2 in duplicate. Western blotting was performed using antibodies to detect the following: HA-RIP140:  $\alpha$ -HA (Bio-Legend, San Diego, CA, USA - 16B12, 1:1500), SUMO1:  $\alpha$ -GMP-1 (Invitrogen, Carlsbad, CA, USA - 332400, 1:500), SUMO2:  $\alpha$ -SUMO2/3 (MBL Life Science, Woburn, MA, USA - M114-3, 1:2000), and GAPDH:  $\alpha$ -GAPDH (Santa Cruz Biotechnology, Inc, Dallas, TX, USA - FL-335, 1:5000). Total wild-type (WT) and mutant NRIP1 protein expression was calculated using GAPDH as loading control. Percentage of SUMOylated NRIP1 relative to total NRIP1 was calculated.

### 2.2.7. ER $\alpha$ luciferase/ $\beta$ -galactosidase reporter assay

Twenty-four hours before transfection, COS-1 cells were seeded onto 12-well plates, and were co-transfected with 200 ng pGL3-ERE3, 20 ng pCMV- $\beta$ -gal, 20 ng pSG5-hER $\alpha$  and pSG5-HA-RIP140-WT or pSG5-HA-RIP140-STOP1087MUT using TransIT-LT1 according to the manufacturer's instructions. Media was replaced with 2.5% charcoal-stripped fetal bovine serum 4 h before transfection, and vehicle/E2 (100 nM) was added 24 h after transfection. Forty-eight hours after transfection, the cells were harvested and lysed in reporter lysis buffer (Promega Corporation, Madison, WI, USA). The cleared supernatants were used for  $\beta$ -galactosidase assays as described previously [16]. Total NRIP1 protein concentration was measured using western blot with  $\alpha$ -HA. The relative LUC activities (i.e. luciferase light units divided by  $\beta$ -galactosidase values or protein concentration) are represented as the means  $\pm$  the standard deviations. The experiments were done in triplicate.

## 3. Results

We analysed the exome of ten patients with isolated POI or DOR. A summary of patient phenotype is shown in Table 1 and a summary of prioritized variants is provided in supplementary material (Supplementary File 2). Nomenclature validation was performed using Variant Validator <https://variantvalidator.org/>.

### 3.1. Diagnoses in known POI genes

#### 3.1.1. Pathogenic homozygous missense *STAG3* variant

In Patient 3, a homozygous variant in *STAG3* (OMIM\*608489) NM\_012447.3:c.962G>A, NP\_036579.2:p.(Arg321His) was identified and predicted to be "pathogenic" after variant curation using ACMG-based criteria (1 PS, 1 PM, and 5 PP). This variant is the focus of another study (manuscript under review).

#### 3.1.2. Likely pathogenic compound heterozygous *GDF9* variants



In Patient 2, we identified two rare heterozygous variants in *GDF9* (OMIM\*601918). Patient 2 experienced primary amenorrhea and was diagnosed with non-syndromic POI at 18 years-old. Her familial pedigree shows, notably, dizygotic twin siblings (Figure 1a). The variants were validated by Sanger sequencing, and cloning demonstrated they were in *trans*, confirming compound heterozygosity (Figure 1b). The nonsense NM\_005260.5:c.794T>G, NP\_005251.1:p.(Leu265Ter) variant falls within the second and last exon of *GDF9* and is therefore predicted escape nonsense-mediated decay (NMD), and instead encode a truncated protein. This truncation impacts the C-terminal mature bioactive domain. The second *GDF9* variant NM\_005260.5:c.1121C>T, NP\_005251.1:p.Pro374Leu, is a missense variant that falls within the TGF $\beta$ -like domain (Figure 1c). ELISA sandwich assay showed a low level in the serum which was not significantly different from that observed in the control (Supplementary File 3) reflecting the sensitivity limit of the assay. The low level of *GDF9* expression in patient's blood precluded further analysis, so we instead investigated the variants *in vitro* using HIS-tagged expression constructs and transient expression in HEK293 cells. Western blot demonstrated that WT *GDF9* could be detected in conditioned media from transfected cells, however, *GDF9*-P374L (p.Pro374Leu) was almost undetectable and *GDF9*-L265\* (p.Leu265Ter) was completely undetectable, indicating the variants impair the formation of *GDF9* and/or its secretion into media (Figure 1d). Recent evidence suggests that in humans *GDF9* is activated by forming a heterodimer called 'cumulin' with the related protein BMP15 [15,19]. Therefore, we also examined heterodimerisation with BMP15. Interestingly, the *GDF9* variants appeared to compromise the expression of BMP15, likely affecting production of BMP15 homodimers and the more active cumulin heterodimer (Figure 1d). Analysis of the precursor and mature *GDF9* indicates successful processing of the WT His-tagged *GDF9*. In contrast, precursor *GDF9*-P374L is detected but no mature protein is evident suggesting this variant impairs *GDF9* dimerisation and/or processing. Both the precursor and mature *GDF9*-L265\* peptide are undetectable suggesting this variant, instead, affects protein formation (Figure 1d). Using ACMG criteria, these compound heterozygous *GDF9* variants are classified as "likely pathogenic" (nonsense variant: 4PM, 1PP and missense variant: 3PM, 3PP). This is only the second described case of biallelic *GDF9* variants associated with POI [20].

### 3.1.3. Pathogenic *FANCM* variants

In patient 5, two nonsense variants in *FANCM* (OMIM\*609644) were identified: NM\_020937.3:c.3088C>T, NP\_065988.1:p.(Arg1030Ter) and NM\_020937.3:c.5791C>T, NP\_065988.1:p.(Arg1931Ter) (Figure 2a). Patient 5 experienced secondary amenorrhea and non-syndromic POI was diagnosed at 25-year-old. Both nonsense variants are rare, but present, in gnomAD

with 0.00003996 (1 het.) and 0.001012 (286 het.) frequency respectively. None of the variants fall within the terminal exon indicating NMD is likely, and suggesting that the patient likely has a lack of FANCM expression. This is in keeping with previously reported patients, sisters with non-syndromic POI harbouring a homozygous LoF allele [21]. Chromosome breakages and rearrangements were higher in our patient than in a control (Figure 2b). The familial history was concordant with a recessive-type condition: while no particular phenotype was noted in the parents, the patient has an older sister diagnosed with non-syndromic POI at 30 years of age. While the c.3088C>T/p.Arg1030Ter is not reported in ClinVar, the c.5791C>T/p.Arg1931Ter variant has three entries, two of which indicate it as pathogenic. The phenotype of the patients in ClinVar with this variant includes Fanconi anemia (uncertain significance), malignant germ cell tumour of the ovary (pathogenic) and spermatogenic failure (pathogenic). Our curation using ACMG-based criteria indicates these variants are “pathogenic”, (each with one very strong criterion (1VS) and 2PS, as well as other supporting criteria) based on predicted LoF, co-occurrence with a second pathogenic variant, the phenotype match with published patients with variants in this gene, functional evidence of chromosomal instability, and the familial history and variant segregation consistent with a recessive-type condition.

#### 3.1.4. Variants of uncertain significance with high clinical relevance in *FSHR*

Patient 4 had two rare moderate-high priority recessive-type variants in a known POI gene, *FSHR* (OMIM \*136435): NM\_000145.3:c.236A>C, NP\_000136.2:p.(Gln79Pro) and NM\_000145.3:c.1771T>C, NP\_000136.2:p.(Phe591Leu) (Supplementary File 4). Patient 4 experienced primary amenorrhea with presence of antral follicles, corresponding to a resistant ovary syndrome (ROS: elevated FSH with normal antral follicle count and normal AMH). *FSHR* belongs to the G protein-coupled receptor family, with an extracellular domain (ECD), a seven helix transmembrane domain (TMD), and an intracellular domain (ICD). The first variant p.(Gln79Pro) falls within a leucine-rich repeat region of the ECD and the second p.(Phe591Leu) falls within the TMD (Supplementary File 4). *In silico* structural analysis using HOPE showed that both variants can affect protein function, due to their location in domains important for the activity of the protein and for p.(Gln79Pro), disturbance of the interactions existing with residues in another domain. Using ACMG-based variant curation criteria, these variants are classed as “variants of uncertain significance with high clinical relevance” (1PM and 3PP each). If these variants could be phased and proven to be in *trans*, the variant categorization would meet criteria to be considered “likely pathogenic” (1PM and 4PP) however, parental DNA was not available, nor was patient RNA that would allow phasing by cloning. The presence of high FSH associated with normal AMH and AFC in the patient, consistent with a diagnosis of ROS, is in favor of variants pathogenicity.

### 3.2. Variants of interest in novel POI genes

Three major candidate genes were noted, each intolerant to LoF variants but harbouring predicted LoF variants in POI patients, and having known roles in ovarian biology. We describe these genes and variants below.

#### 3.2.1. *NRIP1*

A heterozygous nonsense variant in *NRIP1* (OMIM\*602490) NM\_003489.3: c.3259A>T, NP\_003480.2: p.(Lys1087Ter) was identified in Patient 9 (Figure 3a). Disruption of this gene in mice leads to impaired oocyte maturation/ovulation [22]. This LoF variant has not been previously reported (MAF=0). *NRIP1*, encoding a nuclear receptor transcriptional coregulator, is highly intolerant of LoF variation according to gnomAD database with a pLI of 0.99 and a significantly low observed:expected ratio resulting from only four LoF variants recorded compared to the expected 33. Human *NRIP1* contains four transcriptional repression domains and ten interaction motifs (Figure 3b) [23]. The variant is found within the only protein-coding exon of this gene, meaning the transcript likely escapes NMD. We confirmed the stability of variant mRNA by RT-PCR showing retained expression (Figure 3c). The variant lies within the 4<sup>th</sup> repression domain and the predicted truncated protein lacks Lys<sup>1154</sup>, a residue known to be required for SUMOylation [16]. Disruption to this site impairs the ability of *NRIP1* to repress transcription and alters its intranuclear localization in response to SUMO-1 [16]. We investigated whether the patient variant similarly alters *NRIP1* function by introducing the variant into an expression vector and comparing the ability of WT and variant *NRIP1* to be SUMOylated by SUMO1 and SUMO2. SUMOylation of variant *NRIP1* was half as efficient as WT. While ~33% of WT *NRIP1* was SUMOylated by SUMO1, only ~16% of variant *NRIP1* was. Similarly, SUMO2 SUMOylated ~50% of WT *NRIP1* but only ~23% of mutant *NRIP1* (Figure 3d). This demonstrates a clear *in vitro* functional impairment due to the *NRIP1* variant carried by the patient. We also analysed the ability of variant *NRIP1* to act as a co-repressor of ER- $\alpha$ . We used an ER $\alpha$  luciferase/ $\beta$ -galactosidase reporter assay. The addition of estradiol (E2) increases the relative expression from this reporter 14 fold (from 14 to >200 luc/ $\beta$ gal). This E2-induced ER $\alpha$  reporter expression is repressed by the addition of WT *NRIP1*, and the degree of repression increases as the level of *NRIP1* protein increases. The ability of variant *NRIP1* to repress ER $\alpha$  reporter expression in response to E2 is significantly hampered at all expression levels (Figure 3e). Again, this demonstrates that the variant has a clear effect on the *in vitro* function of *NRIP1*. We have demonstrated an impaired function of mutant *NRIP1* and humans are intolerant to LoF variation in this gene. We predict that the gene causes POI due to haploinsufficiency, however, it cannot be known whether the degree of loss of

function is sufficient to induce POI in humans. Further functional work and/or additional human cases with variants in this gene will help to clarify this.

### **3.2.2. *XPO1***

Patient 9 also has a frameshift variant in *XPO1* (OMIM\*602559) NM\_003400.3: c.1693\_1694delGT, NP\_003391.1: p.(Val565SerfsTer2) which has not been previously reported (MAF=0). *XPO1*, a gene also intolerant to LoF, encodes a karyopherin, and is expressed in mouse developing ovary and mammalian oocytes [24,25]. *XPO1* is involved in primordial follicle activation [24] and has a role in germinal vesicle maintenance and meiotic resumption of oocytes [25]. *XPO1* inhibition in porcine oocytes leads to impaired germinal vesicle breakdown due to the lack of nuclear export of maturation-regulating factors [25], further strengthening the link between this gene and ovarian function. Its contribution to the phenotype, alone or in association with *NRIP1*, cannot be ruled out and further functional studies are required to prove its involvement in POI pathogenesis.

### **3.2.3. *MACF1***

One stand-out candidate in Patient 6 was a frameshift variant in *MACF1* (OMIM\*608271), NM\_012090.5:c.5539dupA, NP\_036222.3:p.(Ser1847LysfsTer44). This gene has been implicated in ovarian function in mouse, zebrafish, and fly [26–28]. It is highly intolerant of LoF variation, with only 18 LoF variants detected in gnomAD in contrast to the 318 expected. The variant lies within the 37<sup>th</sup> exon of this large 91-exon gene, and is therefore predicted to induce NMD. Patient RNA was not available for confirmation.

### **3.3. Variants of uncertain significance (VUS)**

The afore-mentioned variants constitute those considered most likely involved in the POI/DOR pathogenesis. There are, however, many other variants that may be involved either in isolation or synergistically. A summary of VUS is presented and discussed in Supplementary Files 2 and 5. We do not provide an exhaustive discussion of VUS and the discussed variants require further functional validation. The small number of patients studied and the genetic heterogeneity of POI meant we did not identify a common genetic defect in these patients. Until additional patients with the same phenotype are identified with variants in the same genes, the involvement of these genes is likely to remain uncertain.

## **4. Discussion**

In this study, we have used WES to investigate the genetic cause of POI in a small cohort of 10 French women. The first analysis focused on 492 POI diagnostic or candidate genes selected from public databases and from literature data. We were successful in identifying the likely genetic cause for three

patients, with novel variants in *STAG3*, *GDF9*, and *FANCM*. One additional patient had variants of uncertain significance with high clinical relevance in a validated POI gene, *FSHR*. These novel variants provide new insights into the genetics of POI.

Our study is the second report of biallelic *GDF9* variants in a patient with POI [20]. *GDF9* is a member of the TGF- $\beta$  superfamily, is critical for mammalian ovarian folliculogenesis, and is a key factor for granulosa cell proliferation and differentiation. *GDF9* is strongly expressed in oocytes at all stages of developing follicles except primordial follicles [29]. Heterozygous variants have been associated with POI, DOR, polycystic ovarian syndrome and mothers of dizygotic twins (DZT) suggesting the involvement of *GDF9* in multiple aspects of ovarian function [29–31]. Reduced expression and/or altered activity of the protein have been proven for most of these variants, with a particularly abrogated expression of *GDF9* harbouring p.Pro374Leu. This variant was significantly more frequent in mothers of DZT suggesting that an enhanced ovulation rate may be associated with reduced *GDF9* signaling. This is true for a naturally occurring *GDF9* variant in sheep, which causes increased fecundity when heterozygous but sterility when homozygous [32]. Interestingly, the mother of patient 7 also had spontaneous DZT. Parental DNA was not available for sequencing, but it is possible that the mother harbours the p.Pro374Leu variant, contributing to her twin pregnancy. Despite the described association of heterozygous variants with ovarian pathology, heterozygous *GDF9* variants have also been observed in healthy women, like the mother and unaffected sister of the reported patient by Franca *et al.* [20], casting doubt on haploinsufficiency of *GDF9* causing POI. The heterozygous *GDF9* variants may be associated with a less severe phenotype (i.e. POI with secondary amenorrhea) whereas biallelic variants may lead to a more severe phenotype, such as primary amenorrhea, as in patient 7. The contribution to a more or less severe phenotype in an allele-dependent manner has recently been suggested for other genes [33].

*FANCM* is a tumor suppressive DNA translocase that controls the outcome of homologous recombination and is involved in the DNA replication process [34]. *Fancm*<sup>-/-</sup> female mice have depletion of primary follicles, impaired folliculogenesis, and abnormal meiotic recombination [21]. Bi-allelic LoF variants have recently been shown to cause non-syndromic POI in women [21], as well as spermatogenic failure in men [35,36] consistent with its role in homologous recombination in both sexes. Only one variant has been described in association with idiopathic POI, limiting the ability to class this gene as diagnostic for curation purposes. We present the second report of *FANCM* variants associated with POI and chromosomal instability, consolidating variants in this gene as a *bone fide* cause. Pathogenic variants are considered as predisposition factors for early onset breast cancer, with monoallelic

nonsense variants in 2.1% of those affected [37]. Heterozygous variants have also been implicated in the development of other cancers such as ovarian cancer [34], and one of the variants carried by Patient 5, in particular, is reported in ClinVar in association with an ovarian germ cell tumour. No history of breast or ovarian cancer was detected in our family; however, the known link between *FANCM* and cancer, along with the evidence of chromosomal instability in our patient, indicates that she may benefit from cancer surveillance.

*FSHR* belongs to the G protein-coupled receptor family, with an extracellular domain, a transmembrane domain, and an intracellular domain. More than 20 inactivating variants have been reported to date, located in the three domains of the protein [38,39]. This gene is one of the few POI genes for which a genotype:phenotype correlation has been suggested [6]. Completely inactivating variants are supposed to cause POI in the context of primary amenorrhea and hypoplastic ovaries, with a block in follicular growth from the primary stage [39,40], whereas partially functional variants have been described in association with a milder phenotype of POI in the context of secondary amenorrhea and normal-sized ovaries, with normal initial follicular development [41]. This is in accordance with the importance of gonadotropins in the late stages of folliculogenesis. Recently, the absence of correlation between *in vitro* FSHR function (complete or partial LoF) and whether ovarian follicles are present cast doubt upon this evidence, highlighting the difficulty to assess *in vivo* ovarian function by *in vitro* studies, and the importance of genetic background [39]. Validated *FSHR* variants have been described in association with resistant ovary syndrome (ROS), which manifests as high FSH but normal ovarian reserve as determined by AMH and AFC [38,39]. The patient described here with two novel *FSHR* variants also presented with this phenotype. Women with ROS should undoubtedly consider undergoing variant screening for *FSHR* [39].

In addition to the variants in validated POI diagnostic genes and the novel insights these have provided, many variants in interesting candidate genes were identified. We propose three new candidate genes involved in POI pathogenesis, *NRIP1*, *XPO1*, and *MACF1*.

*NRIP1* is a widely-expressed hormone-responsive repressor of nuclear receptors of many different nuclear receptors [42–45]. It directly interacts with retinoic acid receptors to suppress retinoic acid-mediated signaling [46], which has a known role in oogenesis [47]. Female mice lacking *Nrip1* (RIPKO mice) are infertile due to a failure to release mature oocytes at ovulation [22]. Importantly, heterozygous RIPKO mice also have impaired ovulation suggesting that an absolute level of *Nrip1* is essential for ovarian function [22]. Haploinsufficiency of *NRIP1* in humans has been associated with congenital anomalies of the kidney and urinary tract in a large family pedigree [48] although ovarian

function was not described. No kidney or urinary tract malformation was noted in the patient of this study. We validated that the variant led to functional impairment *in vitro*. The relevant mouse phenotype, the intolerance of this gene to nonsense variation combined with the predicted severity of the variant and its proven functional impact, provide strong evidence for *NRIP1* as a new candidate gene underpinning human POI pathogenesis.

*XPO1*, also called *CMR1*, is a major nuclear export receptor belonging to the karyopherin  $\beta$  family, with an exportin function. *XPO1* is predicted to recognize about 300 cargos, all harbouring nuclear export signals in their polypeptide chains (leucine-rich-NES) [49]. Misregulation of cargo proteins and misexpression of *XPO1* have been observed in malignancies [49]. The role for karyopherin in the female germline have been demonstrated through studies in mouse oocytes showing *Xpo1* expression in embryonic and adult ovary, and its involvement in regulation of primordial follicle activation [24]. Karyopherin also regulate meiotic entry through appropriate relocation of important cell cycle regulators, and in keeping with this, a key cargo proposed for *XPO1* is *STRA8*, an essential meiotic entry factor [24]. These exportin are also involved in oocyte growth regulation and *XPO1* regulates germinal vesicle maintenance and meiotic resumption of oocytes in pig [25].

*MACF1* is a member of the spectraplakins family of proteins, and is an enormous cytoskeletal protein that interacts with microtubules, actin filaments and intermediate filaments [50]. *Macf1* positively regulates the Wnt- $\beta$  catenin pathway [51] whose disruption causes a POI-like phenotype in mice [26]. Furthermore, deletion of the *MACF1* orthologue in *Zebrafish* leads to aberrant oocyte polarization and subsequent infertility [27]. LoF mutations as well as dominant-negative mutations of the *Drosophila* equivalent of *MACF1*, *Short stop (Shot)*, lead to defects in oogenesis [28]. Other microtubule-binding proteins have been implicated in POI in both humans and other species [52,53]. The roles of microtubule-binding proteins for oocyte function include signal transduction, regulation of the meiotic spindle assembly as well as oocyte polarization. In humans, SNPs affecting the *MACF1* locus have been found to associate with schizophrenia [54], Parkinson's disease [55], and cancers [56]. Pathogenic variants in *MACF1* can cause neurological diseases, spectraplaklinopathy type 1 [57] and lissencephaly [58], however ovarian dysfunction is not described in these patients. The different clinical presentation of the patient described here may be the result of a different consequence of the variant. Indeed, lissencephaly is specifically caused by disruption to the GAR domain, in contrast to the predicted LoF variant identified in our patient. *MACF1*, does indeed, have multiple isoforms and alternative splicing, and the variant described here may have a pronounced effect on an isoform with a predominant role in oocytes, analogous to *TP63* variants that can cause isolated POI or multiorgan syndromes depending on



the nature of the variant and the isoforms it impacts [53]. The relevant role of *MACF1* in ovarian biology, the phenotype of model organisms with *Macf1* disruption, the intolerance of this gene to LoF variant and the severe nature of the detected variant indicate that this gene is a strong POI candidate. Further work is required to establish the role of this gene, and the variant, in human oocyte function.

WES has proven efficacy in POI gene discovery, and has been responsible for the discovery of the majority of human POI genes identified in recent years. WES is also adapted for the diagnosis of genetic diseases with a heterogeneous basis such as POI for which oligogenic origin is often suspected [59]. The overall genetic diagnosis in 3 of 10 patients indicates relative diagnostic success [33,60]. As for previous studies, re-analysis of data in the light of new published literature and using modified analysis protocols is likely to yield additional diagnoses within the data [61,62]. The inability to diagnose some patients is probably the result of 1) the genetic heterogeneity of POI, thereby limiting the ability to confirm gene involvement by identifying multiple unrelated individuals affected by variants in the same gene; 2) incomplete understanding of POI genetics, leading to failure in identifying POI candidates given we prioritized moderate to high impact variants in POI candidate or diagnostic genes, but only high impact variants in the remaining genes and; 3) sequencing of singleton DNA. Without parental DNA to validate compound heterozygosity or to discount maternal inheritance of potential dominant-acting variants, we are limited in our ability to draw conclusions. The *FSHR* variants in Patient 8, for example, could be considered “likely pathogenic” using ACMG criteria if we had parental DNA to demonstrate they are truly compound heterozygous.

In summary, our analysis of women with POI or DOR using WES and stringent ACMG-based criteria to define pathogenicity identified novel likely pathogenic variants in *STAG3*, *GDF9*, and *FANCM*, and variants of uncertain significance with high clinical relevance in *FSHR*. This has provided new insights or strengthened recent claims about the etiology of POI. Being only the second report of biallelic *GDF9* and *FANCM* variants in POI patients, our study validates that these genes are responsible for autosomal recessive POI. We also identify variants of interest in genes never before associated with human POI, in particular *NRIP1*, *XPO1*, and *MACF1*. We provide functional evidence of impaired *NRIP1* activity of the variant protein. This study provides new insights into the genetic basis of POI and multiple avenues for further investigations.



**Contributors**

Sylvie Jaillard conceived and designed the study, acquired the data, analyzed and interpreted the data, and wrote the manuscript.

Katrina Bell analyzed and interpreted the data.

Linda Akloul was involved in patient care and evaluation.

Kelly Walton was involved in the functional studies.

Kenneth McElreavy analyzed and interpreted the data.

William A. Stocker was involved in the functional studies.

Marion Beaumont managed the cytogenetic analysis.

Craig Harrison was involved in the functional studies.

Tiina Jääskeläinen was involved in the functional studies.

Jorma J. Palvimo was involved in the functional studies.

Gorjana Robevska supplied technical support.

Erika Launay managed the cytogenetic analysis.

Anne-Pascale Satié supplied technical support.

Nurin Listyasari supplied technical support.

Claude Bendavid supplied technical support.

Rajini Sreenivasan analyzed and interpreted the data.

Solène Duros was involved in patient care and evaluation.

Jocelyn van den Bergen supplied technical support.

Catherine Henry managed the cytogenetic analysis.

Mathilde Domin-Bernhard was involved in patient care and evaluation.

Laurence Cornevin supplied technical support.

Nathalie Dejuçq-Rainsford was involved in the functional studies.

Marc-Antoine Belaud-Rotureau participated in project supervision.

Sylvie Odent was involved in patient care and evaluation.

Katie L Ayers conceived and designed the study, and analyzed and interpreted the data.

Célia Ravel was involved in patient care and evaluation.

Elena J Tucker conceived and designed the study, acquired the data, analyzed and interpreted the data, wrote the manuscript, and critically reviewed the manuscript.

Andrew H Sinclair conceived and designed the study, participated in the project supervision, and critically reviewed the manuscript.

All authors read and approved the final manuscript.

**Conflict of interest**

The authors declare no conflicts of interest.

**Funding**

This work was supported by CHU Rennes and Rennes 1 University, Faculty of Medicine in France, a Peter Doherty Early Career Fellowship (1054432; to E.J.T.), a National Health and Medical Research Council program grant (1074258; to A.H.S.), a fellowship (1062854; to A.H.S.) from the Australian National Health and Medical Research Council, the Sigrid Jusélius Foundation (JJP), and the Victorian Government's Operational Infrastructure Support Program. WAS was supported by an Australian Government Research Training Program Stipend scholarship.

**Ethical approval**

All procedures were in accordance with the ethical standards of the Ethics Committee of Rennes University Hospital and the French law (favourable opinion from the CCTIRS Comité Consultatif sur le Traitement de l'Information en matière de Recherche dans le domaine de la Santé for the study).

**Provenance and peer review**

This article has undergone peer review.

**Research data (data sharing and collaboration)**

There are no linked research data sets for this paper. Data will be made available on request.

**Acknowledgement**

We would like to thank all the patients and families for taking part in our research.

**References**

- [1] Forabosco A, Sforza C. Establishment of ovarian reserve: a quantitative morphometric study of the developing human ovary. *Fertil Steril* 2007;88:675–83. <https://doi.org/10.1016/j.fertnstert.2006.11.191>.
- [2] Mamsen LS, Lutterodt MC, Andersen EW, Byskov AG, Andersen CY. Germ cell numbers in human embryonic and fetal gonads during the first two trimesters of pregnancy: analysis of six published studies. *Hum Reprod Oxf Engl* 2011;26:2140–5. <https://doi.org/10.1093/humrep/der149>.
- [3] Gunn HM, Tsai M-C, McRae A, Steinbeck KS. Menstrual Patterns in the First Gynecological Year: A Systematic Review. *J Pediatr Adolesc Gynecol* 2018;31:557-565.e6. <https://doi.org/10.1016/j.jpog.2018.07.009>.
- [4] Pastore LM, Christianson MS, Stelling J, Kearns WG, Segars JH. Reproductive ovarian testing and the alphabet soup of diagnoses: DOR, POI, POF, POR, and FOR. *J Assist Reprod Genet* 2018;35:17–23. <https://doi.org/10.1007/s10815-017-1058-4>.
- [5] Faubion SS, Kuhle CL, Shuster LT, Rocca WA. Long-term health consequences of premature or early menopause and considerations for management. *Climacteric J Int Menopause Soc* 2015;18:483–91. <https://doi.org/10.3109/13697137.2015.1020484>.
- [6] Tucker EJ, Grover SR, Bachelot A, Touraine P, Sinclair AH. Premature Ovarian Insufficiency: New Perspectives on Genetic Cause and Phenotypic Spectrum. *Endocr Rev* 2016;37:609–35. <https://doi.org/10.1210/er.2016-1047>.
- [7] Torgerson DJ, Thomas RE, Reid DM. Mothers and daughters menopausal ages: is there a link? *Eur J Obstet Gynecol Reprod Biol* 1997;74:63–6.
- [8] Vegetti W, Grazia Tibiletti M, Testa G, de Lauretis Yankowski null, Alagna F, Castoldi E, et al. Inheritance in idiopathic premature ovarian failure: analysis of 71 cases. *Hum Reprod Oxf Engl* 1998;13:1796–800.
- [9] Pashaiasl M, Ebrahimi M, Ebrahimie E. Identification of the key regulating genes of diminished ovarian reserve (DOR) by network and gene ontology analysis. *Mol Biol Rep* 2016;43:923–37. <https://doi.org/10.1007/s11033-016-4025-8>.
- [10] Jaillard S, Sreenivasan R, Beaumont M, Robevska G, Dubourg C, Knarston IM, et al. Analysis of NR5A1 in 142 patients with premature ovarian insufficiency, diminished ovarian reserve, or unexplained infertility. *Maturitas* 2020;131:78–86. <https://doi.org/10.1016/j.maturitas.2019.10.011>.
- [11] Sadedin SP, Dashnow H, James PA, Bahlo M, Bauer DC, Lonie A, et al. Cpipe: a shared variant detection pipeline designed for diagnostic settings. *Genome Med* 2015;7:68. <https://doi.org/10.1186/s13073-015-0191-x>.
- [12] Quang D, Chen Y, Xie X. DANN: a deep learning approach for annotating the pathogenicity of genetic variants. *Bioinforma Oxf Engl* 2015;31:761–3. <https://doi.org/10.1093/bioinformatics/btu703>.
- [13] Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med Off J Am Coll Med Genet* 2015;17:405–24. <https://doi.org/10.1038/gim.2015.30>.
- [14] Venselaar H, Te Beek TAH, Kuipers RKP, Hekkelman ML, Vriend G. Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfaces. *BMC Bioinformatics* 2010;11:548. <https://doi.org/10.1186/1471-2105-11-548>.
- [15] Mottershead DG, Sugimura S, Al-Musawi SL, Li J-J, Richani D, White MA, et al. Cumulin, an Oocyte-secreted Heterodimer of the Transforming Growth Factor- $\beta$  Family, Is a Potent Activator of Granulosa Cells and Improves Oocyte Quality. *J Biol Chem* 2015;290:24007–20. <https://doi.org/10.1074/jbc.M115.671487>.

- [16] Rytinki MM, Palvimo JJ. SUMOylation modulates the transcription repressor function of RIP140. *J Biol Chem* 2008;283:11586–95. <https://doi.org/10.1074/jbc.M709359200>.
- [17] Patiño LC, Walton KL, Mueller TD, Johnson KE, Stocker W, Richani D, et al. BMP15 Mutations Associated With Primary Ovarian Insufficiency Reduce Expression, Activity, or Synergy With GDF9. *J Clin Endocrinol Metab* 2017;102:1009–19. <https://doi.org/10.1210/jc.2016-3503>.
- [18] Gilchrist RB, Ritter LJ, Cranfield M, Jeffery LA, Amato F, Scott SJ, et al. Immunoneutralization of growth differentiation factor 9 reveals it partially accounts for mouse oocyte mitogenic activity. *Biol Reprod* 2004;71:732–9. <https://doi.org/10.1095/biolreprod.104.028852>.
- [19] Peng J, Li Q, Wigglesworth K, Rangarajan A, Kattamuri C, Peterson RT, et al. Growth differentiation factor 9:bone morphogenetic protein 15 heterodimers are potent regulators of ovarian functions. *Proc Natl Acad Sci U S A* 2013;110:E776-785. <https://doi.org/10.1073/pnas.1218020110>.
- [20] França MM, Funari MFA, Nishi MY, Narcizo AM, Domenice S, Costa EMF, et al. Identification of the first homozygous 1-bp deletion in GDF9 gene leading to primary ovarian insufficiency by using targeted massively parallel sequencing. *Clin Genet* 2018;93:408–11. <https://doi.org/10.1111/cge.13156>.
- [21] Fouquet B, Pawlikowska P, Caburet S, Guigon C, Mäkinen M, Tanner L, et al. A homozygous FANCM mutation underlies a familial case of non-syndromic primary ovarian insufficiency. *ELife* 2017;6. <https://doi.org/10.7554/eLife.30490>.
- [22] White R, Leonardsson G, Rosewell I, Ann Jacobs M, Milligan S, Parker M. The nuclear receptor co-repressor nrip1 (RIP140) is essential for female fertility. *Nat Med* 2000;6:1368–74. <https://doi.org/10.1038/82183>.
- [23] Nautiyal J. Transcriptional coregulator RIP140: an essential regulator of physiology. *J Mol Endocrinol* 2017;58:R147–58. <https://doi.org/10.1530/JME-16-0156>.
- [24] Mihalas BP, Western PS, Loveland KL, McLaughlin EA, Holt JE. Changing expression and subcellular distribution of karyopherins during murine oogenesis. *Reprod Camb Engl* 2015;150:485–96. <https://doi.org/10.1530/REP-14-0585>.
- [25] Onuma A, Fujioka YA, Fujii W, Sugiura K, Naito K. Effects of exportin 1 on nuclear transport and meiotic resumption in porcine full-grown and growing oocytes. *Biol Reprod* 2018;98:501–9. <https://doi.org/10.1093/biolre/iox168>.
- [26] Tomizuka K, Horikoshi K, Kitada R, Sugawara Y, Iba Y, Kojima A, et al. R-spondin1 plays an essential role in ovarian development through positively regulating Wnt-4 signaling. *Hum Mol Genet* 2008;17:1278–91. <https://doi.org/10.1093/hmg/ddn036>.
- [27] Gupta T, Marlow FL, Ferriola D, Mackiewicz K, Dapprich J, Monos D, et al. Microtubule actin crosslinking factor 1 regulates the Balbiani body and animal-vegetal polarity of the zebrafish oocyte. *PLoS Genet* 2010;6:e1001073. <https://doi.org/10.1371/journal.pgen.1001073>.
- [28] Lee J, Lee S, Chen C, Shim H, Kim-Ha J. shot regulates the microtubule reorganization required for localization of axis-determining mRNAs during oogenesis. *FEBS Lett* 2016;590:431–44. <https://doi.org/10.1002/1873-3468.12086>.
- [29] Belli M, Shimasaki S. Molecular Aspects and Clinical Relevance of GDF9 and BMP15 in Ovarian Function. *Vitam Horm* 2018;107:317–48. <https://doi.org/10.1016/bs.vh.2017.12.003>.
- [30] Simpson CM, Robertson DM, Al-Musawi SL, Heath DA, McNatty KP, Ritter LJ, et al. Aberrant GDF9 expression and activation are associated with common human ovarian disorders. *J Clin Endocrinol Metab* 2014;99:E615-624. <https://doi.org/10.1210/jc.2013-3949>.
- [31] Wang T-T, Ke Z-H, Song Y, Chen L-T, Chen X-J, Feng C, et al. Identification of a mutation in GDF9 as a novel cause of diminished ovarian reserve in young women. *Hum Reprod* 2013;28:2473–81. <https://doi.org/10.1093/humrep/det291>.
- [32] Hanrahan JP, Gregan SM, Mulsant P, Mullen M, Davis GH, Powell R, et al. Mutations in the genes for oocyte-derived growth factors GDF9 and BMP15 are associated with both increased ovulation

- rate and sterility in Cambridge and Belclare sheep (*Ovis aries*). *Biol Reprod* 2004;70:900–9. <https://doi.org/10.1095/biolreprod.103.023093>.
- [33] Jolly A, Bayram Y, Turan S, Aycan Z, Tos T, Abali ZY, et al. Exome Sequencing of a Primary Ovarian Insufficiency Cohort Reveals Common Molecular Etiologies for a Spectrum of Disease. *J Clin Endocrinol Metab* 2019;104:3049–67. <https://doi.org/10.1210/jc.2019-00248>.
- [34] Basbous J, Constantinou A. A tumor suppressive DNA translocase named FANCM. *Crit Rev Biochem Mol Biol* 2019;54:27–40. <https://doi.org/10.1080/10409238.2019.1568963>.
- [35] Kasak L, Punab M, Nagirnaja L, Grigorova M, Minajeva A, Lopes AM, et al. Bi-allelic Recessive Loss-of-Function Variants in FANCM Cause Non-obstructive Azoospermia. *Am J Hum Genet* 2018;103:200–12. <https://doi.org/10.1016/j.ajhg.2018.07.005>.
- [36] Yin H, Ma H, Hussain S, Zhang H, Xie X, Jiang L, et al. A homozygous FANCM frameshift pathogenic variant causes male infertility. *Genet Med Off J Am Coll Med Genet* 2019;21:62–70. <https://doi.org/10.1038/s41436-018-0015-7>.
- [37] Schubert S, van Luttikhuisen JL, Auber B, Schmidt G, Hofmann W, Penkert J, et al. The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants. *Int J Cancer* 2019;144:2683–94. <https://doi.org/10.1002/ijc.31992>.
- [38] Flageole C, Toufaily C, Bernard DJ, Ates S, Blais V, Chénier S, et al. Successful in vitro maturation of oocytes in a woman with gonadotropin-resistant ovary syndrome associated with a novel combination of FSH receptor gene variants: a case report. *J Assist Reprod Genet* 2019;36:425–32. <https://doi.org/10.1007/s10815-018-1394-z>.
- [39] He W-B, Du J, Yang X-W, Li W, Tang W-L, Dai C, et al. Novel inactivating mutations in the FSH receptor cause premature ovarian insufficiency with resistant ovary syndrome. *Reprod Biomed Online* 2019;38:397–406. <https://doi.org/10.1016/j.rbmo.2018.11.011>.
- [40] Touraine P, Beau I, Gougeon A, Meduri G, Desroches A, Pichard C, et al. New natural inactivating mutations of the follicle-stimulating hormone receptor: correlations between receptor function and phenotype. *Mol Endocrinol Baltim Md* 1999;13:1844–54. <https://doi.org/10.1210/mend.13.11.0370>.
- [41] Beau I, Groyer-Picard M-T, Desroches A, Condamine E, Leprince J, Tomé J-P, et al. The basolateral sorting signals of the thyrotropin and luteinizing hormone receptors: an unusual family of signals sharing an unusual distal intracellular localization, but unrelated in their structures. *Mol Endocrinol Baltim Md* 2004;18:733–46. <https://doi.org/10.1210/me.2003-0130>.
- [42] Cavallès V, Dauvois S, L'Horset F, Lopez G, Hoare S, Kushner PJ, et al. Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. *EMBO J* 1995;14:3741–51.
- [43] Lee CH, Chinpaisal C, Wei LN. Cloning and characterization of mouse RIP140, a corepressor for nuclear orphan receptor TR2. *Mol Cell Biol* 1998;18:6745–55. <https://doi.org/10.1128/mcb.18.11.6745>.
- [44] Subramaniam N, Treuter E, Okret S. Receptor interacting protein RIP140 inhibits both positive and negative gene regulation by glucocorticoids. *J Biol Chem* 1999;274:18121–7. <https://doi.org/10.1074/jbc.274.25.18121>.
- [45] Treuter E, Albrechtsen T, Johansson L, Leers J, Gustafsson JA. A regulatory role for RIP140 in nuclear receptor activation. *Mol Endocrinol Baltim Md* 1998;12:864–81. <https://doi.org/10.1210/mend.12.6.0123>.
- [46] Lee CH, Wei LN. Characterization of receptor-interacting protein 140 in retinoid receptor activities. *J Biol Chem* 1999;274:31320–6. <https://doi.org/10.1074/jbc.274.44.31320>.
- [47] Miyauchi H, Ohta H, Nagaoka S, Nakaki F, Sasaki K, Hayashi K, et al. Bone morphogenetic protein and retinoic acid synergistically specify female germ-cell fate in mice. *EMBO J* 2017;36:3100–19. <https://doi.org/10.15252/embj.201796875>.

- [48] Vivante A, Mann N, Yonath H, Weiss A-C, Getwan M, Kaminski MM, et al. A Dominant Mutation in Nuclear Receptor Interacting Protein 1 Causes Urinary Tract Malformations via Dysregulation of Retinoic Acid Signaling. *J Am Soc Nephrol JASN* 2017;28:2364–76. <https://doi.org/10.1681/ASN.2016060694>.
- [49] Fung HYJ, Chook YM. Atomic basis of CRM1-cargo recognition, release and inhibition. *Semin Cancer Biol* 2014;27:52–61. <https://doi.org/10.1016/j.semcancer.2014.03.002>.
- [50] Hu L, Su P, Li R, Yin C, Zhang Y, Shang P, et al. Isoforms, structures, and functions of versatile spectraplakins MACF1. *BMB Rep* 2016;49:37–44. <https://doi.org/10.5483/BMBRep.2016.49.1.185>.
- [51] Chen H-J, Lin C-M, Lin C-S, Perez-Olle R, Leung CL, Liem RKH. The role of microtubule actin cross-linking factor 1 (MACF1) in the Wnt signaling pathway. *Genes Dev* 2006;20:1933–45. <https://doi.org/10.1101/gad.1411206>.
- [52] Iwase S, Sato R, De Bock P-J, Gevaert K, Fujiki S, Tawada T, et al. Activation of ADF/cofilin by phosphorylation-regulated Slingshot phosphatase is required for the meiotic spindle assembly in *Xenopus laevis* oocytes. *Mol Biol Cell* 2013;24:1933–46. <https://doi.org/10.1091/mbc.E12-12-0851>.
- [53] Tucker EJ, Jaillard S, Grover SR, den Bergen J, Robevska G, Bell KM, et al. TP63-truncating variants cause isolated premature ovarian insufficiency. *Hum Mutat* 2019. <https://doi.org/10.1002/humu.23744>.
- [54] Costas J, Suárez-Rama JJ, Carrera N, Paz E, Páramo M, Agra S, et al. Role of DISC1 interacting proteins in schizophrenia risk from genome-wide analysis of missense SNPs. *Ann Hum Genet* 2013;77:504–12. <https://doi.org/10.1111/ahg.12037>.
- [55] Wang X, Li N, Xiong N, You Q, Li J, Yu J, et al. Genetic Variants of Microtubule Actin Cross-linking Factor 1 (MACF1) Confer Risk for Parkinson's Disease. *Mol Neurobiol* 2017;54:2878–88. <https://doi.org/10.1007/s12035-016-9861-y>.
- [56] Miao Z, Ali A, Hu L, Zhao F, Yin C, Chen C, et al. Microtubule actin cross-linking factor 1, a novel potential target in cancer. *Cancer Sci* 2017;108:1953–8. <https://doi.org/10.1111/cas.13344>.
- [57] Jørgensen LH, Mosbech M-B, Færgeman NJ, Graakjaer J, Jacobsen SV, Schrøder HD. Duplication in the microtubule-actin cross-linking factor 1 gene causes a novel neuromuscular condition. *Sci Rep* 2014;4:5180. <https://doi.org/10.1038/srep05180>.
- [58] Dobyens WB, Aldinger KA, Ishak GE, Mirzaa GM, Timms AE, Grout ME, et al. MACF1 Mutations Encoding Highly Conserved Zinc-Binding Residues of the GAR Domain Cause Defects in Neuronal Migration and Axon Guidance. *Am J Hum Genet* 2018;103:1009–21. <https://doi.org/10.1016/j.ajhg.2018.10.019>.
- [59] Robevska G, van den Bergen JA, Ohnesorg T, Eggers S, Hanna C, Hersmus R, et al. Functional characterization of novel NR5A1 variants reveals multiple complex roles in disorders of sex development. *Hum Mutat* 2018;39:124–39. <https://doi.org/10.1002/humu.23354>.
- [60] Patiño LC, Beau I, Carlosama C, Buitrago JC, González R, Suárez CF, et al. New mutations in non-syndromic primary ovarian insufficiency patients identified via whole-exome sequencing. *Hum Reprod Oxf Engl* 2017;32:1512–20. <https://doi.org/10.1093/humrep/dex089>.
- [61] Delcour C, Amazit L, Patiño LC, Magnin F, Fagart J, Delemer B, et al. ATG7 and ATG9A loss-of-function variants trigger autophagy impairment and ovarian failure. *Genet Med Off J Am Coll Med Genet* 2019;21:930–8. <https://doi.org/10.1038/s41436-018-0287-y>.
- [62] Wang B, Li L, Zhu Y, Zhang W, Wang X, Chen B, et al. Sequence variants of KHDRBS1 as high penetrance susceptibility risks for primary ovarian insufficiency by mis-regulating mRNA alternative splicing. *Hum Reprod Oxf Engl* 2017;32:2138–46. <https://doi.org/10.1093/humrep/dex263>.

Journal Pre-proof

Legend to Figures and Tables




Figure 1a








Figure 1b





- No functional studies
- \* Weak reduction of expression
- \*\* Strong reduction of expression
- \*\*\* Loss of expression
- Nonsense variants

Figure 1c




Figure 1d

### Figure 1. Likely pathogenic variants in *GDF9*.

#### 1a: Familial pedigree of Patient 2

The proband is indicated by an arrow. Small solid black circles represent voluntary termination of pregnancy (II5, II6, and II7) or miscarriage (III3). Information on height is given for individuals II2, II1, II2, II3 and II4. Years of birth are indicated for the sibling II1, II2, II3, and II4. GH: growth hormone.

#### 1b: Sequencing results of Patient 2

Top: IGV visualization of the *GDF9* variants in Patient 2, showing variants physically close to each other

Middle: Sanger sequencing of *GDF9* in Patient 2 confirming the presence of heterozygous variants

Bottom: Variant phasing, showing phased variants, and confirming compound heterozygosity (presence of one variant per clone, each clone corresponding to one line)

1c: Gene diagram showing variants position with respect to previously reported variants involved in POI (premature ovarian insufficiency), DOR (diminished ovarian reserve), PCOS (polycystic ovarian syndrome), and DZT (dizygotic twin). Reported variants are heterozygous except one homozygous (hom.) NH2: Amino terminal domain, COOH: Carboxy terminal domain. One star: functional studies

showing weak reduction of expression, two stars: functional studies showing strong reduction of expression, three stars: functional studies showing loss of expression, underline: non-sense variants, bold: variants observed in our patient.

**1d:** Western blot of GDF9 *in vitro* expression

Left: Variants impair protein production/secretion in conditioned media. Detection of WT GDF9 (rhGDF9: recombinant human and GDF9-His8: HIS-tagged GDF9) and poor/absent detection of GDF9-P374L and GDF9-L265\* (black box), indicating the variants impair the production of GDF9 and/or its secretion into conditioned media.

Middle: Analysis of precursor and mature GDF9 intracellularly. Successful processing of WT HIS-tagged GDF9 (3). Detection of precursor GDF9-P374L without detection of mature protein suggesting impaired processing (4). Absence of detection of precursor and mature GDF9-L265\* confirming lack of expression resulting from premature stop codon (5).

Right: Variants impair BMP15-GDF9 interaction intracellularly. Detection of HIS-tagged BMP15 and WT GDF9 indicating they complement each other. Weak detection of HIS-tagged BMP15 and either GDF9-P374L or GDF9-L265\* (black box), indicating the complementary interaction is not achieved with mutant GDF9.




Figure 2a





Figure 2b

**Figure 2. Pathogenic variants in *FANCM*.**

**2a:** Sanger sequencing of *FANCM* in Patient 5 confirming the presence of heterozygous variants

**2b:** Karyotype with induction of chromosome breakage by using mitomycin C. Breakages are indicated by asterisks.



c.3259A>T

Figure 3a

Journal Pre-proof




Figure 3b






Figure 3c




Figure 3d




Figure 3e

**Figure 3. NRIP1 is a candidate gene.**

**3a:** Sanger sequencing of *NRIP1* in Patient 9 confirming the presence of heterozygous variant

**3b:** NRIP1 protein diagram (according to InterPro description <https://www.ebi.ac.uk>) and variants location observed in human with respect to protein domains. Grey boxes: transcriptional repression domains (RD1-4). Small dot lines: nine interaction motifs LxxLL. Large dot line: interaction motif LxxML. CAKUT: Congenital Anomalies of the Kidney and Urinary Tract. POI: Premature Ovarian Insufficiency. Stars: Small Ubiquitin-like Modifier acceptor lysines.

**3c:** RT-PCR proving transcript stability. A clear expression of both the mutant and wild-type sequence in patient cDNA is observed on both electrophoresis (top) showing a unique same-sized band as in the control and on sequencing with RT-PCR (bottom). Negative controls without reverse transcriptase (-RT) confirm lack of residual gDNA contributing to the sequencing products.

**3d:** *In vitro* evidence of variant impact, Western blot. Line A: percentage of NRIP1 SUMOylated relative to total NRIP1. Line B: total WT and variant NRIP1 expression (unSUMOylated and SUMOylated forms, relative to GAPDH).  $\alpha$ -HA,  $\alpha$ -SUMO1,  $\alpha$ -SUMO2, and  $\alpha$ -GAPDH: antibodies. ~33% of WT NRIP1 is

SUMOylated by SUMO1 and ~50% by SUMO2 (black arrows), ~16% of variant NRIP1 is SUMOylated by SUMO1 and ~23% by SUMO2 (dotted arrows). Asterisks indicate SUMOylated forms of NRIP1. For analysis, total amount of NRIP1 was first determined by measuring the bands close to 130kDa as well as the larger bands closer to 170kDa (unSUMOylated + SUMOylated NRIP1). This was expressed relative to GAPDH expression and relative to wild-type unSUMOylated sample (Lane 1).

**3e:** *In vitro* evidence of variant impact, ER $\alpha$ -dependent luciferase reporter. Variant *NRIP1* is less efficient in repressing estradiol (E2)-induced transcription by ER $\alpha$ . The addition E2 increases the relative expression from this reporter by 14-fold (from 14 to >200 luc/ $\beta$ gal) (1). E2-induced ER $\alpha$ -dependent reporter expression is repressed by the addition of WT NRIP1, and the degree of repression increases as the level of NRIP1 protein increases (2). The ability of variant NRIP1 to repress ER $\alpha$ -dependent reporter expression in response to E2 is significantly hampered at all expression levels (3).

**Table I:** Summary of the clinical and molecular findings for the 10 patients of the study.

	Patient 1 (POI)	Patient 2 (POI)	Patient 3 (POI)	Patient 4 (POI)	Patient 5 (POI)	Patient 6 (POI)	Patient 7 (POI)	Patient 8 (POI)	Patient 9 (POI/DOR)	Patient 10 (DOR)
Menstruation	Primary amenorrhea	Primary amenorrhea	Primary amenorrhea	Primary amenorrhea	Secondary amenorrhea	Secondary amenorrhea	Secondary amenorrhea	Secondary amenorrhea	N	N
FSH UI/l	95	68.5	46.5	56.9	61	31	49.8	91.5	30.1	9.3
LH UI/l	30	55	24.5	39.1	52	NA	83.4	47.4	5.9	4.3
E2 pg/ml	11	Low	33	24.5	25.2	15.8	152.7	9	<20	62
AMH ng/ml	<0.03	<0.4	NA	3.2	<0.1	0.4	0.3	<0.4	0.4	0.8
Prolactine ng/ml	NA	6.7 (N)	N	NA	10.1 (N)	NA	NA	20.9 (N)	24.3 (high) → 19.4 (N)	27 (high) → 19.3 (N)
US	Small uterus and ovaries without follicles	Endometrial atrophy AFC=0	Small uterus Small right ovary with small follicles Atrophic left ovary (not seen)	AFC=6	Normal uterus, small ovaries without follicles	Small ovaries without follicles	NA	NA	AFC=4	AFC=10
Age at diagnosis	17	18	15	20	24	37	29	26	29	33
Age of maternal menopause	Reported normal	Reported normal	50	NA	55	55	55	NA	NA	40
Karyotype	46,XX	46,XX	46,XX	46,XX	46,XX	46,XX	46,XX	46,XX	46,XX	46,XX
<i>FMR1</i> screening	N	N	N	N	N	N	N	N	N	N
Microarray	N	N	N	N	N	N	N	N	N	N
Auto-Ab	NA	NA	TPO-, TG-	NA	TPO- 21OH- Ovarian-Ab-	TPO-, TG- 21OH-	ACA- 21OH-	TPO-, TG- 21OH-	TPO- Ovarian-Ab-	TPO-, TG- ACA-
Medical history	No spontaneous puberty Primary infertility Hashimoto thyroiditis	OD program	OD program	Primary infertility OD program	Menarche 11 yo Primary infertility OD program	Menarche 12 yo 1 child (spontaneous pregnancy) OD program	Menarche 11 yo Primary infertility OD program	Menarche 12 yo Pierre Robin sequence Secondary hearing loss OD program	Menarche 13 yo Primary infertility Cervical hernia Strabismus OD program	Menarche 12 yo 1 child, 2 miscarriages, 1 VTP (other partner)
Familial history	/	Three miscarriages in the mother, one healthy brother, twins sibling	Consanguineous parents One infertile brother (non-obstructive)	/	One sister with POI at 28 yo No history of breast cancer	/	/	/	/	One infertile paternal aunt

		(sister with one miscarriage, brother with small size and strabismus)	azoospermia)							
<sup>a</sup> Genes of interest	<i>TAF4B, IRS4, ZNF462, ZNF462, SOHLH1</i>	<b><i>GDF9</i></b>	<b><i>STAG3</i></b>	<b><i>FSHR, ERCC6-PGBD3, NUP50</i></b>	<b><i>AMH, MCM8, FANCM</i></b>	<b><i>COL4A6, POLG, MACF1</i></b>	<b><i>ERCC6-PGBD3, BMPR1B, FSHR</i></b>	<b><i>DCAF1 (VPRBP), NUP107, PARP1, PNPLA7</i></b>	<b><i>NRIP1, RSPO1, XPO1</i></b>	<b><i>SGOL2, PRLR, NUP107, ADAMTS1</i></b>

Table 1

<sup>a</sup>Refer to Supplementary File 2 for variant details. Bold indicates diagnostic variants and/or variants for which there is substantial support for gene involvement in POI pathogenesis.

FSH: follicle stimulating hormone, LH: luteinizing hormone, E2: estradiol, AMH: anti-Müllerian hormone, US: ultrasound, AFC: antral follicular count, N: normal, NA: non-available, Ab: antibody, TPO: anti-thyroperoxidase, TG: anti-thyroglobuline, yo: years old, OD: oocyte donation, VTP: voluntary termination of pregnancy, POI: premature ovarian insufficiency, DOR: diminished ovarian reserve

**Supplementary File 1: Detailed method for phasing by cloning**

**Supplementary File 2: Summary of variants of interest**

**Supplementary File 3: GDF9 ELISA assay**

**Supplementary File 4: Variants of uncertain significance of *FSHR***

**Supplementary File 5: Discussion of variants of interest in unsolved patients**